1. Tumor microenvironment promotes breast cancer chemoresistance

   • Umar Mehraj
   • Abid Hamid Dar
   • Manzoor A. Mir

   Review Article 09 January 2021 Pages: 147 - 158

   

2. Disulfiram: a novel repurposed drug for cancer therapy

   • Chen Lu
   • Xinyan Li
   • Xiao Zhang

   Review Article 10 January 2021 Pages: 159 - 172

   

3. Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid

   • Milene Volpato
   • Nicola Ingram
   • Mark A Hull

   Original Article Open access 11 October 2020 Pages: 173 - 184

   

4. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types

   • Nadia Terranova
   • Mendel Jansen
   • Bart S. Hendriks

   Original Article Open access 04 November 2020 Pages: 185 - 196

   

5. Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors

   • Timothy Crook
   • Andrew Gaya
   • Dadasaheb Akolkar

   Original Article Open access 10 November 2020 Pages: 197 - 205

   

6. PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1

   • Shuo Yu
   • Yang Li
   • Lan Yang

   Original Article 21 November 2020 Pages: 207 - 215

   

7. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma

   • Haofeng Lu
   • Lin Zhou
   • Yufeng Yuan

   Original Article 23 November 2020 Pages: 217 - 228

   

8. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients

   • Nastja Lunar
   • Marie-Christine Etienne-Grimaldi
   • Antonin Schmitt

   Original Article 02 January 2021 Pages: 229 - 239

   

9. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers

   • Naveed Shaik
   • Robert R. LaBadie
   • Geoffrey Chan

   Original Article Open access 03 January 2021 Pages: 241 - 250

   

10. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer

    • Akira Yamagata
    • Toshihide Yokoyama
    • Tadashi Ishida

    Original Article 04 January 2021 Pages: 251 - 258

    

11. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair

    • Gloria Ciniero
    • Ahmed H. Elmenoufy
    • Lars Petter Jordheim

    Original Article 05 January 2021 Pages: 259 - 267

    

12. Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

    • R. B. Verheijen
    • T. T. van Duijl
    • A. D. R. Huitema

    Original Article 23 January 2021 Pages: 269 - 276

    

13. Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane

    • Maria Spiliotaki
    • Galatea Kallergi
    • Vassilis Georgoulias

    Original Article 29 January 2021 Pages: 277 - 287

    

14. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

    • Malvi Savani
    • Katti Woerner
    • Keith M. Skubitz

    Short Communication 03 January 2021 Pages: 289 - 294